Search

everythinglearnresearchcommunity

for

Search:↓

PTEN was identified as a specific marker for the skin disease cutaneous lupus erythematosus, and it helps increase the expression of harmful type I interferons.

Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.

New technologies show potential for better understanding and treating skin conditions with abnormal mucin, but more research is needed for clinical use.

Alopecia areata may be caused by the immune system attacking hair follicles.

The CD44-CD49d complex boosts T cell activation and survival in autoimmune disease.

Age-related immune changes worsen Parkinson's disease, suggesting new treatment strategies.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

T-cell patterns in skin help distinguish alopecia areata from androgenetic alopecia.

Chronic graft-versus-host disease in the skin shows strong Th1 immune response and unique barrier issues.

Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.

Three molecular subtypes of advanced skin T-cell lymphoma were identified, with potential biomarkers for predicting treatment response and disease progression.

The study found that sweat glands normally suppress immune responses, but this is disrupted in certain skin diseases, possibly contributing to their development.

Alopecia areata is an autoimmune disease where T cells attack hair follicles.

Autoimmune reactions may cause both alopecia areata and HAM.

Common gene patterns may cause skin autoimmune diseases.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

Alopecia areata is linked to immune system differences, with specific biomarkers like CXCL9 and CXCL10 being key for diagnosis and potential treatment targets.

B cells can both help and hinder the body's defense against melanoma.

Biological therapy boosts the immune system to effectively fight melanoma.

Immunosuppressive therapy helps manage autoimmune diseases but carries risks like infection and potential for malignancy.

Targeting specific biomarkers and immune signals is more effective and safer for treating inflammatory skin diseases.

Mast cells and CD8 T cells interact closely in skin diseases, affecting each other's behavior and contributing to conditions like psoriasis and eczema.

Nanomedicine-based immunotherapy shows promise in improving tissue repair and regeneration.

The immune system plays a key role in tissue repair, affecting both healing quality and regenerative ability.

Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.

Local inflammation worsens autoimmune skin conditions by increasing antibody buildup.